{"id":57594,"date":"2024-07-25T00:04:22","date_gmt":"2024-07-25T00:04:22","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/07\/25\/transcode-therapeutics-inc-announces-closing-of-public-offering\/"},"modified":"2024-07-25T00:04:22","modified_gmt":"2024-07-25T00:04:22","slug":"transcode-therapeutics-inc-announces-closing-of-public-offering","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/","title":{"rendered":"TransCode Therapeutics, Inc. Announces Closing of Public Offering"},"content":{"rendered":"<div>\n<p align=\"justify\">BOSTON, July  24, 2024  (GLOBE NEWSWIRE) &#8212; TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (\u201cTransCode\u201d or the \u201cCompany\u201d), a clinical-stage RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.30 per share, for gross proceeds of $3,000,000, before deducting placement agent fees and offering expenses.<\/p>\n<p align=\"justify\">The Company intends to use the net proceeds from the offering primarily for product development activities, including one or more clinical trials with TTX-MC138, its lead therapeutic candidate, and related investigational new drug (IND) enabling studies, and for working capital and other general corporate purposes.<\/p>\n<p align=\"justify\">ThinkEquity acted as sole placement agent for the offering.<\/p>\n<p align=\"justify\">The offering was made pursuant to an effective shelf registration statement that has been filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d). The final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC&#8217;s website at http:\/\/www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from ThinkEquity, 17 State Street, 41<sup>st<\/sup> Floor, New York, New York 10004 Attention: Prospectus Department.<\/p>\n<p align=\"justify\">This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.<\/p>\n<p align=\"justify\"><strong>About TransCode Therapeutics, Inc.<br \/><\/strong>TransCode Therapeutics, Inc. (Nasdaq: RNAZ) is a clinical-stage oncology company focused on treating metastatic disease. The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The Company\u2019s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.<\/p>\n<p align=\"justify\"><strong>Forward-Looking Statements<br \/><\/strong>This press release contains \u201cforward-looking statements\u201d as defined by the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as \u201cbelieve,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cdesign,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cobjective,\u201d \u201cplan\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these terms and similar expressions intended to identify forward-looking statements. These forward-looking statements include statements related to the intended use of the net proceeds. TransCode cautions readers that forward-looking statements are based on management\u2019s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, risks related to prevailing market conditions, the impact of general economic, industry or political conditions in the United States, and various other factors, and the continued listing of the Company\u2019s common stock on the Nasdaq Capital Market. These and other risks and uncertainties are described more fully in the sections titled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the registration statement and in the prospectus supplement related to the offering described herein, and in the Company\u2019s annual report on Form 10-K, quarterly report on Form 10-Q and other reports filed with the SEC. Forward-looking statements reflect the Company\u2019s analysis only on their stated date, and TransCode undertakes no obligation to update or revise these statements except as may be required by law.<\/p>\n<p align=\"justify\"><strong>Investor Relations:<\/strong><\/p>\n<p align=\"justify\">TransCode Therapeutics, Inc.<br \/>Tania Montgomery-Hammon<br \/>VP Business Development<br \/>Tania.montgomery@transcodetherapeutics.com<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MmFkMGEzYmMtY2I4YS00YWU1LWJlZjAtNWFkYWFkZDMyYTAyLTEyMTkyMDM=\/tiny\/TransCode-Therapeutics-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, July 24, 2024 (GLOBE NEWSWIRE) &#8212; TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (\u201cTransCode\u201d or the \u201cCompany\u201d), a clinical-stage RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.30 per [&#8230;]\n","protected":false},"author":1,"featured_media":57595,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-57594","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>TransCode Therapeutics, Inc. Announces Closing of Public Offering - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TransCode Therapeutics, Inc. Announces Closing of Public Offering\" \/>\n<meta property=\"og:description\" content=\"BOSTON, July 24, 2024 (GLOBE NEWSWIRE) &#8212; TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (\u201cTransCode\u201d or the \u201cCompany\u201d), a clinical-stage RN\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-25T00:04:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/07\/TransCode-Therapeutics-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"TransCode Therapeutics, Inc. Announces Closing of Public Offering\",\"datePublished\":\"2024-07-25T00:04:22+00:00\",\"dateModified\":\"2024-07-25T00:04:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/\"},\"wordCount\":637,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/\",\"name\":\"TransCode Therapeutics, Inc. Announces Closing of Public Offering - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-07-25T00:04:22+00:00\",\"dateModified\":\"2024-07-25T00:04:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TransCode Therapeutics, Inc. Announces Closing of Public Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TransCode Therapeutics, Inc. Announces Closing of Public Offering - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/","og_locale":"en_US","og_type":"article","og_title":"TransCode Therapeutics, Inc. Announces Closing of Public Offering","og_description":"BOSTON, July 24, 2024 (GLOBE NEWSWIRE) &#8212; TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (\u201cTransCode\u201d or the \u201cCompany\u201d), a clinical-stage RN","og_url":"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-07-25T00:04:22+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/07\/TransCode-Therapeutics-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"TransCode Therapeutics, Inc. Announces Closing of Public Offering","datePublished":"2024-07-25T00:04:22+00:00","dateModified":"2024-07-25T00:04:22+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/"},"wordCount":637,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/","url":"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/","name":"TransCode Therapeutics, Inc. Announces Closing of Public Offering - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-07-25T00:04:22+00:00","dateModified":"2024-07-25T00:04:22+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/transcode-therapeutics-inc-announces-closing-of-public-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"TransCode Therapeutics, Inc. Announces Closing of Public Offering"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/57594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=57594"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/57594\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/57595"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=57594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=57594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=57594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}